Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3.
Product Name: Tofacitinib |Catalog Number: DC8736 |CAS 477600-75-2 |Other names: CP-690550; Tofacitinib; tasocitinib |Chemical Name: 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |Molecule Formular: C16H20N6O |MW: 312.37
Tofacitinib (trade name Xeljanz, Formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved For the treatment of rheumatoid arthritis (RA) in the United States and is being studied For treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as For the prevention of organ transplant rejection.For the detailed information of Tofacitinib (CP-690550) Citrate, the solubility of Tofacitinib (CP-690550) Citrate in water, the solubility of Tofacitinib (CP-690550) Citrate in DMSO, the solubility of Tofacitinib (CP-690550) Citrate in PBS buffer, the animal experiment (test) of Tofacitinib (CP-690550) Citrate, the cell expriment (test) of Tofacitinib (CP-690550) Citrate, the in vivo, in vitro and clinical trial test of Tofacitinib (CP-690550) Citrate, the EC50, IC50,and Affinity of Tofacitinib (CP-690550) Citrate, Please contact DC Chemicals.
For research only, not for human use!
没有评论:
发表评论